AI Terminal
ABIVAX
AGM Information • Jun 7, 2021
1063_rns_2021-06-07_68e6df4c-4bf3-44f5-9b06-5325a63e3a7f.html
AGM Information
Open in ViewerOpens in native device viewer
News Details
Corporate | 7 June 2021 18:00
Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting
DGAP-News: ABIVAX / Key word(s): AGM/EGM
07.06.2021 / 18:00
The issuer is solely responsible for the content of this announcement.
Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting
Shareholders approved all proposed resolutions
PARIS, France, June 7, 2021 – 6:00 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, held its ordinary annual and extraordinary general meeting of shareholders on June 4, 2021, which was chaired by Philippe Pouletty, Chairman of the Board of directors, without the physical presence of the shareholders.
The shareholders have adopted all the resolutions approved by the Board of Directors and, in particular, the financial statements for the 2020 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of Directors related to financial transactions.
Shareholders also approved the reappointments of Philippe Pouletty, Truffle Capital, Santé Holding SRL and Corinna Zur Bonsen-Thomas as Board members.
Details on the vote results will be available on the company’s website.
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.
Contacts
| Abivax Communications Regina Jehle [email protected] +33 6 24 50 69 63 |
Investors LifeSci Advisors Chris Maggos [email protected] +41 79 367 6254 |
Press Relations & Investors Europe MC Services AG Anne Hennecke [email protected] +49 211 529 252 22 |
| Public Relations France Actifin Ghislaine Gasparetto [email protected] +33 6 21 10 49 24 |
Public Relations France DGM Conseil Thomas Roborel de Climens [email protected] +33 6 14 50 15 84 |
Public Relations USA Rooney Partners LLC Marion Janic [email protected] +1 212 223 4017 |
07.06.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de